AI assistant
Lyell Immunopharma, Inc. — Director's Dealing 2021
Jun 17, 2021
33362_dirs_2021-06-16_782f6ccc-6089-4625-b16a-0295fae89a36.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-16
Reporting Person: Hill Stephen J. (Chief Technical Ops. Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (right to buy) | $3.65 | 2029-07-09 | Common Stock (500000) | Direct | |
| Option (right to buy) | $3.65 | 2030-01-15 | Common Stock (165000) | Direct | |
| Option (right to buy) | $5.96 | 2030-11-16 | Common Stock (450000) | Direct | |
| Option (right to buy) | $6.24 | 2031-02-11 | Common Stock (100000) | Direct | |
| Option (right to buy) | $12.67 | 2031-04-13 | Common Stock (85000) | Direct |
Footnotes
F1: 1/4 of the option shares vested on June 19, 2020, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.
F2: The shares vest in equal monthly installments over the forty-eight months following February 1, 2020.
F3: The shares vest in equal monthly installments over the forty-eight months following December 1, 2020.
F4: The shares vest in equal monthly installments over the forty-eight months following March 1, 2021.
F5: The shares vest in equal monthly installments over the forty-eight months following April 14, 2021.